Who are CNTO 148's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Infliximab and immunosuppressives, SB5, Adalimumab and its biosimilars, Adalimumab (ADA), Adalimumab (Humira), Infliximab biosimilar.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cnto-148.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

CNTO 148 — Competitive Intelligence Brief

CNTO 148 (CNTO 148) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TNF-α inhibitor (monoclonal antibody). Area: Immunology.

phase 3 TNF-α inhibitor (monoclonal antibody) TNF-α (Tumor Necrosis Factor-alpha) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

CNTO 148 (CNTO 148) — Janssen Pharmaceutical K.K.. CNTO 148 is a monoclonal antibody that blocks tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling in immune-mediated diseases.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
CNTO 148 TARGET	CNTO 148	Janssen Pharmaceutical K.K.	phase 3	TNF-α inhibitor (monoclonal antibody)	TNF-α (Tumor Necrosis Factor-alpha)
Infliximab and immunosuppressives	Infliximab and immunosuppressives	Children's Hospital of Fudan University	marketed	TNF-α inhibitor (monoclonal antibody) + immunosuppressive agents	TNF-α receptor (via infliximab); multiple targets depending on co-administered immunosuppressive
SB5	SB5	Samsung Bioepis Co., Ltd.	marketed	TNF-α inhibitor (monoclonal antibody); biosimilar	TNF-α (tumor necrosis factor-alpha)
Adalimumab and its biosimilars	Adalimumab and its biosimilars	Hanyang University Seoul Hospital	marketed	TNF-α inhibitor (monoclonal antibody)	TNF-α (tumor necrosis factor-alpha)
Adalimumab (ADA)	Adalimumab (ADA)	JHSPH Center for Clinical Trials	marketed	TNF-α inhibitor (monoclonal antibody)	TNF-α (tumor necrosis factor-alpha)
Adalimumab (Humira)	Adalimumab (Humira)	Tufts Medical Center	marketed	TNF-α inhibitor (monoclonal antibody)	TNF-α (Tumor Necrosis Factor-alpha)
Infliximab biosimilar	Infliximab biosimilar	Hanyang University Seoul Hospital	marketed	TNF-α inhibitor (monoclonal antibody)	TNF-α (tumor necrosis factor-alpha)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TNF-α inhibitor (monoclonal antibody) class)

Merck Sharp & Dohme LLC · 3 drugs in this class
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 2 drugs in this class
Hanyang University Seoul Hospital · 2 drugs in this class
Biocad · 1 drug in this class
Children's Memorial Health Institute, Poland · 1 drug in this class
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives · 1 drug in this class
Centocor, Inc. · 1 drug in this class
Hikma Pharmaceuticals LLC · 1 drug in this class
Hospital de Manises · 1 drug in this class
Celltrion · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CNTO 148 — Competitive Intelligence Brief. https://druglandscape.com/ci/cnto-148. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab